Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

ROCHE HOLDINGS AG : Bank of America reiterates its Buy rating

share with twitter share with LinkedIn share with facebook
01/21/2020 | 09:30am EDT

In a research note, Bank of America analyst Sachin Jain has maintained his recommendation on the stock with a Buy rating.. The target price is revised upwards from CHF 360 to CHF 345.

© MarketScreener with dpa-AFX Analyser 2020

Stocks mentioned in the article
ChangeLast1st jan.
BANK OF AMERICA CORPORATION 0.68% 23.7 Delayed Quote.-33.16%
LETS HOLDINGS GROUP CO., LTD. -4.72% 8.28 End-of-day quote.37.09%
LOOK HOLDINGS INCORPORATED -0.62% 958 End-of-day quote.-23.48%
ROCHE HOLDING AG 0.29% 294.75 Delayed Quote.-6.40%
share with twitter share with LinkedIn share with facebook
All news about ROCHE HOLDING AG
11:43aGLOBAL MARKETS LIVE : Alphabet, Amazon, Starbucks…
10:44aCHUGAI PHARMACEUTICAL : Results from the Investigator-Initiated Phase I Study of..
AQ
08:46aROCHE : SAP, Roche and Tenthpin Partner to Create New Standard for Clinical Tria..
AQ
10/29REGENERON PHARMACEUTICALS : COVID-19 Outpatient Trial Prospectively Demonstrates..
AQ
10/29CHUGAI PHARMACEUTICAL : Contribution of Para-transit Vehicles to Welfare Service..
AQ
10/29ROCHE HOLDINGS AG : UBS keeps its Buy rating
MD
10/29ROCHE : Tecentriq in combination with Avastin approved in China for people with ..
AQ
10/29REGENERON'S REGN-COV2 ANTIBODY COCKT : Prospective data from ongoing Phase 2/3 C..
PU
10/29ROCHE : Tecentriq in combination with Avastin approved in China for people with ..
PU
10/29ROCHE : Tecentriq in combination with Avastin approved in China for people with ..
AQ
More news
Financials
Sales 2020 60 216 M 65 656 M 65 656 M
Net income 2020 14 527 M 15 839 M 15 839 M
Net cash 2020 3 238 M 3 530 M 3 530 M
P/E ratio 2020 17,7x
Yield 2020 3,17%
Capitalization 252 B 275 B 275 B
EV / Sales 2020 4,13x
EV / Sales 2021 3,80x
Nbr of Employees 97 735
Free-Float 83,6%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 379,06 CHF
Last Close Price 293,90 CHF
Spread / Highest target 48,3%
Spread / Average Target 29,0%
Spread / Lowest Target -3,03%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
Paul Bulcke Non-Executive Director
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG-6.40%274 461
JOHNSON & JOHNSON-5.95%361 159
PFIZER INC.-9.95%196 047
MERCK & CO., INC.-16.56%191 944
NOVARTIS AG-22.62%176 518
NOVO NORDISK A/S9.93%154 639